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treatment regimen. Here, BDD-rFVIII patients consumed a
median of 6204 IU/kg per year while matched FL-rFVIII patients
utilized a median of 4118 IU/kg (p = 0.03). This difference could
not be attributed to a higher prescribed prophylaxis dose. CON-
CLUSIONS: This analysis shows that BDD-rFVIII-treated
patients were associated with utilizing more IU/kg/year of FVIII
while on a prophylactic regimen than matched FL-rFVIII-treated
patients. Further research is required to determine whether
greater utilization of BDD-rFVIII during prophylaxis is associ-
ated with increased risk of breakthrough bleeds.
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OBJECTIVES: The objective of this study was to examine the
age-speciﬁc relationship between body mass index (BMI), preva-
lence of metabolic disorders, and utilization of outpatient ser-
vices. METHODS: Data for this study came from the National
Health Interview Survey in Taiwan, which was conducted in
2001. With the consent of the respondents, the interview data
were linked to their claims in the National Health Insurance
database. The self-reported weight and height were used to cal-
culated BMI. Diseases and utilization of outpatient services were
identiﬁed from the claims data. RESULTS: A linear trend of
prevalence was observed with increments of BMI. The same
trend was observed for the number of visits to outpatient clinics.
The BMI-related medical expenditures did not reach statistical
signiﬁcance. Nevertheless, age was an important factor. After
controlling for the number of chronic diseases, the relationship
between BMI and utilization of outpatient services disappeared.
CONCLUSIONS: The BMI-related medical expenditures per-
tained to metabolic disorders, such as hypertension, diabetes,
and ischemic heart diseases. A health promotion program should
prevent the diseases, thus reducing medical expenditures.
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OBJECTIVES: To contrast the factors that are associated with
metabolic syndrome risk for US adolescents overall and US His-
panic adolescents. METHODS: At risk is deﬁned as having three
or more of the following: elevated fasting glucose, elevated SBP,
elevated DBP, elevated triglycerides, elevated BMI, elevated waist
circumference, or low HDL. Logistic regression and NHANES
2003–2006 data were used to examine the impact on metabolic
syndrome risks; gender, race, ethnicity, immigrant status, income,
insurance, parental education, activity levels, number of school
lunches and breakfasts per week, milk consumption, language
preference, and number of meals outside the home per week. US
adolescents overall are compared with US Hispanic adolescents.
A signiﬁcance level of 0.05 was used. Weighted sample sizes for
Hispanic adolescents and US born adolescents are 8,178,714 and
50,837,204 respectively. RESULTS: The results of the regressions
were vastly different between US adolescents and US Hispanic
(First Generation and Native) adolescents. All variables in the
models are signiﬁcant. Major differences include the decreased
risk (42%) for US adolescent females overall, and the increased
risk (17%) for US Hispanic females. Notably, for those Hispanics
that are ﬁrst generation, their risk is increased by 65%. For US
adolescents overall, low or middle income levels increase risk
three times, while low and middle income level US Hispanic
adolescents have a risk decrease of 77% and 69% respectively.
For every meal eaten outside the home per week (excluding
school meals) the risk increases for US adolescents by 4% and by
13% for Hispanic US adolescents. CONCLUSIONS: These ado-
lescents are at risk for acute cardiovascular endpoints, higher
medical utilization and expenditure, and lower quality of life.
Interventions should focus on education regarding healthy eating
outside the home with limited resources. A surprising result of
this analysis is the high price of acculturation for Hispanic ﬁrst
generation adolescents.
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OBJECTIVES: To estimate the incremental costs following bari-
atric surgery, with regard to antidepressant use. METHODS:
Data was collected for body weight, mental health status such as
depression, medication use and counselling for one hundred sub-
jects pre and post bariatric surgery from 2006–2007. Measures
of mental health were compared before and after surgery. Cost
estimates for the management of depression were based on data
published in 2000. RESULTS: Patients lost a mean value of 52%
of their excess body weight. Following surgery, the proportion
of depressed patients decreased by 46%, the proportion of the
patients on antidepressants decreased by 30%, and the propor-
tion of those who utilized counselling services decreased by 19%.
When applying cost estimates for managing depression, total
incremental savings in depression management were $6,527
(average per patient per year estimate). CONCLUSIONS: Bari-
atric surgery is a costly procedure estimated at $22,213 per
procedure. Results from a Western New York center based on
100 patients suggest that reduction in depression and the asso-
ciated medication and counselling use provide incremental
savings of $6527 (per year) for the patients who have the pro-
cedure. In addition, co-morbidities associated with obese patients
such as diabetes, hypertension, sleep apnea, and venous insufﬁ-
ciency offer further incremental savings which is likely to offset
the cost of the bariatric surgery, possibly leading to savings.
Long-term outcomes of bariatric surgery and the associated
incremental cost were not evaluated in this study. Future research
should consider long-term outcomes and associated costs from
the societal, payer and patient perspectives. Maintaining the
weight loss over the long-term is likely to lead to signiﬁcant cost
savings from all perspectives and improved quality of life.
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OBJECTIVES: On October 26, 2005, Arkansas Medicaid imple-
mented a preferred drug list (PDL) policy for long acting narcotic
analgesics (LANA) where only generic long-acting morphine and
methadone could be obtained without prior-approval. The objec-
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tive was to determine the impact of the PDL on net costs and
utilization of LANA, total narcotic analgesics, and non-narcotic
substitute drugs. METHODS: We obtained Arkansas Medicaid
claims data from January 2003 to July 2007. Net costs based on
CMS-rebates and mg of morphine equivalents (MEq) obtained
from standardized conversion tables were the primary outcome
variables. Autoregressive-integrated-moving-average ARIMA
time series models of monthly measures were estimated. Inter-
rupted OLS time series models were estimated to capture the
impact of the policy on the shifts in trend and intercept.
RESULTS: There were 709,791 Medicaid eligibles, of which
3,227 used a LANA whom had an average age of 44.65 years,
39.36% male, and 80.54% white. The PDL was associated with
a $1.41 million (95%CI: $0.37–$2.43 million) and a $1.78
million (95%CI: $0.48–$3.05 million) cost reduction for LANA
and total narcotic analgesics over the 22-month post-policy
period. Total narcotic utilization was not signiﬁcantly different
than trend utilization for 18 months of the post-policy period.
The PDL was associated with a signiﬁcant increase in C-II short-
acting narcotic utilization of 202,828 (95%CI: 68,160–337,497)
MEq and non-signiﬁcant decreases in C-II LANA and CIII-V
narcotic utilization. A sensitivity analysis with a term to capture
the effect of generic fentanyl availability yielded more conserva-
tive cost saving estimates. There was no PDL-related increase
in the utilization of benzodiazepines, migraine agents, NSAIDs,
muscle-relaxants, anticonvulsants, or antidepressants. CON-
CLUSIONS: The PDL resulted in signiﬁcant cost savings for
narcotic analgesics. The policy did not consistently affect the
overall level of narcotic analgesia prescribed, however, the policy
may have steered patients toward shorter acting narcotics.
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OBJECTIVES: To evaluate health care resource use, costs and
patient-reported outcomes (PRO’s) among patients with neuro-
pathic pain, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups in Germany. METHODS: Patients were
consecutively recruited by physicians in general practice (n = 47)
in 2005. Data on resource utilization due to neuropathic pain
was collected retrospectively for six months. Costs were esti-
mated from the societal perspective. PRO were assessed through
generic SF-36 and disease-speciﬁc von Korff Index, and Patient
Health Questionnaire Depression (PHQ-D) questionnaires at
time of recruitment. Groups were compared using multivariable
general linear modeling (GLM). RESULTS: Ninety-nine patients
took part in this study (n = 44 self-treatment, n = 23 guideline,
n = 32 non-guideline-groups). The majority of patients were
overweight, 61% of all patients were women, and 29% were
currently employed. Average duration of neuropathic pain was
about 6.2 years and was comparable among the groups. Patients
in the self-treatment-group were younger than patients in guide-
line or non-guideline-group (mean age 54.5 vs. 67.6 vs. 66.9
years, p < 0.0001). Mean total costs per patient and 6 months
were €674.23 [95%CI 225.95; 1122.51] vs. €1507.21 [95%CI
715.48; 2298.94] vs. €1426.24[95%CI 850.18; 2002.30] (self-
treatment-vs. guideline vs. non-guideline-group, respectively,
p = 0.0092, by GLM adjusted by age and BMI). PRO as evalu-
ated by von Korff Index and PHQ-D were better in the self-
treatment-group patients. The groups did not differ in the mean
component scores of SF-36. CONCLUSIONS: Patients in self-
treatment-group in this study had the lowest societal mean total
costs per patient and better PRO’s (as evaluated by von Korff
Index and PHQ-D) compared to other groups. No major differ-
ences were detected between guideline and non-guideline
patients.
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OBJECTIVES: To assess PRO and costs in German patients with
back pain, speciﬁcally for guideline, non-guideline, and self-
treatment-groups. METHODS: Patients (n = 145) were recruited
by physicians in general practice (n = 54) in 2005. Resource
utilization data due to back pain was collected retrospectively
for six months. Patients completed the generic SF-36, and
the disease-speciﬁc Hannover Functional Questionnaire (FFbH),
von Korff Index and Patient Health Questionnaire Depression
(PHQ-D) forms at the time of enrollment. Groups were com-
pared using multivariable general linear modeling (GLM).
RESULTS: Patients (n = 72 self-treatment, n = 29 guideline-,
n = 44 non-guideline-groups) were on average 54 years old,
64% of them were women. Patients with self-treatment were
younger, more likely to be employed and had lower BMI than
patients in guideline or non-guideline-group (mean age 49.8 vs.
59.4 vs. 57.4 years; mean BMI 24.9 vs. 28.2 vs. 26.8). Average
duration of back pain was about 7.3 years and was comparable
among the groups. The groups differed regarding the SF-36, the
von Korff index, FFbH-R and frequency of PHQ-D somatoform
symptoms. The self-treatment group reported the highest mean
physical component of the SF-36 compared to other groups
(39.6  10.4, p = 0.0011, adjusted by age). Mean total societal
perspective costs per patient were (€417.61 [95%CI 171.03;
664.18] vs. €3159.17 [95%CI 933.62; 5384.73] vs. €1640.58
[95%CI 818.02; 2463.13], self-treatment-vs. guideline vs. non-
guideline-group, respectively). The major cost factors were: in
the self-treatment-group, reduction of earning capacity (43.4%),
sport activities (26.9%), and remedies (19.3%); in the guideline-
group, sick leaves (64.0%), prescribed medications (10.1%), and
visits to physicians (6.2%); and in the non-guideline-group,
sick leaves (23.8%), remedies (20.7%), and reduction of earn-
ing capacity (12.7%). CONCLUSIONS: PRO seem to be better
and costs lower in self-treatment-group. The major cost
factors are different among guideline, non-guideline and self-
treatment-groups, while costs are positively related to age and
unemployment.
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OBJECTIVES: Renal impairment after transplant is associated
to a greater risk of death. It is of interest to asses how and when
the diagnosis is made. To evaluate the diagnostic method of renal
dysfunction (Clinical or Histological). METHODS: Observa-
tional and multicenter study including 872 renal transplant
patients with at least two years post-transplant. Data were ret-
rospectively collected at ﬁve time pointssince transplant. Clini-
Abstracts A649
